Original 2025 and 2026 interim earnings announcements disclose drug-discovery solutions revenue and group results.
Mainland ChinaFull profile →
China-listed CRO/CDMO · Companies
Matching companies load automatically. Browse 24 companies per page; expand filters to narrow the results.
Search & refine Filters update automatically
Disease tags identify mentions in recorded facts or pipeline text, not approved indications or a complete pipeline. Platform service providers may have no disease-specific tag.
71 matching companiesShowing 1–24 / 71
Provides research services using DEL, FBDD/SBDD, and other small-molecule discovery platforms and emerging technologies, alongside proprietary discovery and translation.
Mainland ChinaFull profile →
The group provides CRDMO services spanning small-molecule research and manufacturing, biology, preclinical testing, and clinical research. Financials are consolidated group figures.
Mainland China / United StatesFull profile →
Combines structural biology and discovery CRO, Langhua CDMO/CMC, and incubation/investment. Investment fair-value changes affect group profit.
Mainland ChinaFull profile →
An integrated platform combining laboratory services, CMC and small-molecule CDMO, clinical research, and biologics/cell and gene therapy services.
Mainland ChinaFull profile →
Principal platforms include life science services/products, ProBio biologics and advanced-therapy CRDMO, and Bestzyme industrial synthetic biology.
United States / Mainland ChinaFull profile →
Building on small-molecule CDMO, the company provides research and manufacturing for peptides, oligonucleotides, antibodies, conjugates, and drug products.
Mainland ChinaFull profile →
Provides CDMO services for small-molecule APIs and drug products, cell and gene therapies, peptides, oligonucleotides, and conjugates.
Mainland ChinaFull profile →
Clinical CRO services include operations, regulatory affairs, pharmacovigilance, data management and statistics, SMO, and laboratories. Frontage is consolidated.
Mainland ChinaFull profile →
Provides biologics discovery, development, and manufacturing CRDMO services. Consolidated financials include the separately listed WuXi XDC.
Mainland China / United States / Germany / IrelandFull profile →
CDMO services cover small molecules, peptides, conjugates, and oligonucleotide therapeutics. The group also sells APIs; group financials are not equivalent to a stand-alone CDMO segment.
Mainland ChinaFull profile →
A diversified pharmaceutical platform combining API intermediates, CDMO, drug products, outsourced research and manufacturing, and proprietary product lines.
Mainland ChinaFull profile →
ChemPartner Pharmatech provides discovery, CMC, preclinical, and related research services through operating entities including Shanghai ChemPartner.
Mainland ChinaFull profile →
Provides ADC and other bioconjugate discovery, process development, and GMP manufacturing, including antibody intermediates and payload-linker capabilities.
Mainland ChinaFull profile →
Combines products and services across tool compounds, biochemical reagents, molecular building blocks, and API/intermediate/drug-product research and manufacturing.
Mainland ChinaFull profile →
Extends molecular building-block products into medicinal chemistry, process development, and GMP API/drug-product manufacturing, including continuous-flow technology.
Mainland ChinaFull profile →
Provides one-stop drug development, regulatory submissions, and CMC/process services, based on clinical and preclinical research capabilities.
Mainland ChinaFull profile →
Pharmaceutical research subsidiaries provide discovery, CMC, clinical trials, BE/PK bioanalysis, SMO, and marketing authorization holder-related services.
Mainland ChinaFull profile →
Provides outsourced drug development, clinical, and CMC services, with CDMO and technology commercialization through subsidiaries including Saimer Pharmaceuticals.
Mainland ChinaFull profile →
Focuses on clinical trial site management (SMO), providing coordination and project execution for sponsors and clinical sites.
Mainland ChinaFull profile →
Provides CMC, clinical operations, SMO, biosample analysis, data management/statistics, technology commercialization, and collaborative development.
Mainland ChinaFull profile →
Operates in medicinal and synthetic chemistry, DMPK, process development, and commercial manufacturing, alongside proprietary generic drug research, production, and sales.
Mainland ChinaFull profile →
Combines gene-edited animal-model products and preclinical services with RenMice antibody discovery, licensing/transfers, and collaborative development.
Mainland ChinaFull profile →
The annual report discloses peptide drug CDMO, generic peptide APIs, and drug products; group financials include proprietary products.
Mainland ChinaFull profile →
Coverage expands from sourced records; this database does not claim all biopharma companies.